Products - Metastases | Topic

Showing 30 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
22 May 2025
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2025
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
29 April 2025
Expected publication date:
24 July 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 December 2025
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Metastases Products

Showing 30 products

Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]

Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

Lifileucel for previously treated unresectable or metastatic melanoma ID3863

Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]

Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

Fruquintinib for previously treated metastatic colorectal cancer ID6274

Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452

Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Metastases Products

Showing 30 products